Black Diamond Therapeutics Inc - Understand $bdtx stock

$BDTX Market Cap: $267.3 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$80.55M

TTM

Current Assets

$126.8M

Q2 2024

Current Liabilities

$18.44M

Q2 2024

Current Ratio

687.42%

Q2 2024

Total Assets

$150.0M

Q2 2024

Total Liabilities

$38.97M

Q2 2024

Book Value

$111.0M

Q2 2024

Cash

$32.81M

Q2 2024

P/E

-3.318

Sep 18, 2024 EST

Free Cash Flow

-$32.35M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017
Selling, General & Admin	$27.11M	$28.39M	$30.04M	$21.36M	$7.580M	$1.950M	$670.0K
YoY Change	-4.51%	-5.5%	40.65%	181.79%	288.72%	191.04%
% of Gross Profit
Research & Development	$59.35M	$64.44M	$96.83M	$48.21M	$21.75M	$6.950M	$3.450M
YoY Change	-7.89%	-33.45%	100.85%	121.62%	212.99%	101.45%
% of Gross Profit
Depreciation & Amortization	$437.0K	$508.0K	$205.0K	$52.00K	$47.00K	$44.00K	$20.00K
YoY Change	-13.98%	147.8%	294.23%	10.64%	6.82%	120.0%
% of Gross Profit
Operating Expenses	$86.46M	$92.83M	$126.9M	$69.57M	$29.33M	$8.904M	$4.120M
YoY Change	-6.86%	-26.83%	82.37%	137.18%	229.42%	116.12%
Operating Profit	-$86.46M	-$92.83M	-$126.9M	-$69.57M	-$29.33M	-$8.904M
YoY Change	-6.86%	-26.83%	82.37%	137.18%	229.42%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017
Interest Expense	$1.924M	-$219.0K	$0.00	$1.000K	$0.00	-$10.00K	-$200.0K
YoY Change	-978.54%		-100.0%		-100.0%	-95.0%
% of Operating Profit
Other Income/Expense, Net	$4.018M	$3.909M	$1.276M	$2.316M	-$5.926M	-$27.00K	-$10.00K
YoY Change	2.79%	206.35%	-44.91%	-139.08%	21848.15%	170.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017
Pretax Income	-$82.64M	-$91.27M	-$125.3M	-$66.99M	-$35.26M	-$8.930M	-$4.600M
YoY Change	-9.46%	-27.18%	87.08%	89.99%	294.85%	94.13%
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$82.44M	-$91.17M	-$125.6M	-$67.25M	-$35.26M	-$8.931M	-$4.600M
YoY Change	-9.57%	-27.41%	86.75%	90.75%	294.78%	94.15%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.88	-$2.52	-$3.47	-$2.05
Diluted Earnings Per Share	-$1.88	-$2.52	-$3.47	-$2.05	-$1.080M	-$273.6K	-$140.9K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017
Cash & Short-Term Investments	$131.4M	$122.8M	$209.8M	$315.1M	$154.7M	$51.70M	$7.900M
YoY Change	7.0%	-41.46%	-33.42%	103.68%	199.23%	554.43%
Cash & Equivalents	$56.22M	$34.32M	$65.80M	$34.60M	$154.7M	$51.70M	$7.900M
Short-Term Investments	$75.18M	$88.49M	$144.0M	$280.5M
Other Short-Term Assets	$2.634M	$4.899M	$5.917M	$4.500M	$1.000M	$0.00	$0.00
YoY Change	-46.23%	-17.2%	31.49%	350.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$134.0M	$127.7M	$215.7M	$319.6M	$155.7M	$51.70M	$7.900M
YoY Change	4.96%	-40.8%	-32.51%	105.27%	201.16%	554.43%
Property, Plant & Equipment	$23.71M	$27.38M	$30.74M	$8.800M	$200.0K	$100.0K	$100.0K
YoY Change	-13.41%	-10.93%	249.32%	4300.0%	100.0%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$823.0K	$1.168M	$1.239M	$1.300M	$2.400M	$0.00	$0.00
YoY Change	-29.54%	-5.73%	-4.69%	-45.83%
Total Long-Term Assets	$24.53M	$28.55M	$31.98M	$10.10M	$2.600M	$100.0K	$100.0K
YoY Change	-14.07%	-10.73%	216.62%	288.46%	2500.0%	0.0%
Total Assets	$158.6M	$156.3M	$247.7M	$329.7M	$158.3M	$51.80M	$8.000M
YoY Change
Accounts Payable	$2.324M	$1.877M	$4.107M	$2.500M	$2.000M	$400.0K	$200.0K
YoY Change	23.81%	-54.3%	64.28%	25.0%	400.0%	100.0%
Accrued Expenses	$17.32M	$13.38M	$19.54M	$11.70M	$2.900M	$500.0K	$200.0K
YoY Change	29.42%	-31.49%	66.97%	303.45%	480.0%	150.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.65M	$15.26M	$23.64M	$14.20M	$4.900M	$2.600M	$2.200M
YoY Change	28.73%	-35.45%	66.49%	189.8%	88.46%	18.18%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$22.19M	$25.30M	$28.14M	$7.700M	$0.00	$4.000M	$0.00
YoY Change	-12.31%	-10.1%	265.45%		-100.0%
Total Long-Term Liabilities	$22.19M	$25.30M	$28.14M	$7.700M	$0.00	$4.000M	$0.00
YoY Change	-12.31%	-10.1%	265.45%		-100.0%
Total Liabilities	$41.83M	$40.56M	$51.78M	$21.90M	$4.900M	$6.600M	$2.200M
YoY Change	3.13%	-21.67%	136.45%	346.94%	-25.76%	200.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020
Basic Shares Outstanding	43.95M shares	36.33M shares	36.19M shares	32.91M shares
Diluted Shares Outstanding	43.95M shares	36.33M shares	36.19M shares	32.91M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $267.27 Million

About Black Diamond Therapeutics Inc

Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 54 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The firm is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The firm is also focused on a development candidate against an undisclosed, validated oncogene.

Industry: Biological Products, (No Diagnostic Substances) Peers: Mink Therapeutics Inc Harvard Apparatus Regenerative Technology Inc Cyteir Therapeutics, Inc. Genprex Inc Ibio Inc Passage Bio Inc TCR2 THERAPEUTICS INC. Taysha Gene Therapies Inc